MBX 4291

Phase 2Small molecule

MMBX Biosciences

MBX 4291 is one of 49 small molecule programs targeting Obesity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObesityActive, not recruiting

HypoparathyroidismActive, not recruiting

ObesityPhase 1

Active, not recruiting

HypoparathyroidismPhase 2

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Actemra

Roche

Preclinical

2 2

Avapro

Sanofi

Preclinical

1 3

Calciferol

Alnylam Pharmaceuticals

Amidate

Adenocard

Colcrys

Alnylam Pharmaceuticals

Activella

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 9

MBX 4291

MMBX Biosciences

Phase 2

1 10

Oxycontin

PProtega

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Obesity1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

Recruiting·MMBX Biosciences·Phase 1·NCT07142707·64 enrolled

Impaired Renal Function1 trial

Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

Completed·MMBX Biosciences·Phase 1·NCT06496217·25 enrolled

Hypoparathyroidism1 trial

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

Completed·MMBX Biosciences·Phase 2·NCT06465108·64 enrolled

Adult Subject1 trial

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects

Completed·MMBX Biosciences·Phase 1·NCT05158335·76 enrolled

Hypoglycemia1 trial

A Phase 2a, Open-label, Exploratory Study to Evaluate Preliminary Efficacy of Subcutaneous MBX 1416 in Patients With Postbariatric Hypoglycemia (The STEADI Study)

Completed·MMBX Biosciences·Phase 2·NCT07029412·20 enrolled

1 more indication

Unspecified1 trial

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects

Completed·MMBX Biosciences·Phase 1·NCT06036784·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for MBX 4291. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MBX 4291 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MBX 4291. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MBX Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMBX Biosciences

MBX 4291

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Obesity1 trial

Impaired Renal Function1 trial

Hypoparathyroidism1 trial

Adult Subject1 trial

Hypoglycemia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News